Also known as DES(1-3)IGF-1 · des-IGF-1 · DES(1-3) IGF-1
A truncated IGF-1 missing its first three residues — sharply reduced IGFBP binding and high local potency, but short-acting.
Research refreshed
IGF-1 DES (DES(1-3)IGF-1) is native IGF-1 with the first three N-terminal residues removed — a 67-amino-acid analog. Losing that tripeptide sharply reduces its affinity for the IGF-binding proteins that normally restrain IGF-1, leaving it far more potent locally, though much shorter-acting than the extended LR3 analog.
IGF-1 DES is the shortest of the common IGF-1 variants: insulin-like growth factor 1 with the first three amino acids (Gly-Pro-Glu) clipped from the N-terminus, giving a 67-residue peptide versus 70 for native IGF-1. That small deletion has an outsized effect, because the N-terminal tripeptide is part of what IGF-binding proteins grip. Removing it drops IGFBP affinity dramatically, so the peptide stays free and active rather than being sequestered.
The result is a variant reported as roughly ten-fold more potent than native IGF-1 in some assays, but with a short half-life — the opposite design philosophy to IGF-1 LR3, which is engineered for extended, systemic action. IGF-1 DES is a research compound (~7.4 kDa), widely used in cell culture, not FDA-approved, and prohibited in sport.
IGF-1 receptor agonism with greatly reduced IGFBP binding → potent, short-lived local anabolic signaling.
Behind every vial of IGF-1 DES is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how IGF-1 DES, specifically, is brought into being.
On paper, IGF-1 DES weighs in at roughly 7,371.5 daltons. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Assembling IGF-1 DES means roughly 67 coupling cycles on the synthesizer — one protected residue added at a time, which is also 67 chances for an incomplete coupling to seed a deletion impurity. At this length the growing chain is prone to aggregation on the resin, making every later cycle harder — long sequences are where small per-cycle losses compound into a messy crude. It also carries a disulfide bridge, an extra step beyond a plain chain that adds both capability and cost.
The crude mixture — IGF-1 DES plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one. IGF-1 DES carries 6 cysteines, whose thiols are oxidation-sensitive and can form disulfide links — reactive chemistry that purification has to control rather than ignore. It also contains oxidation-prone methionine or tryptophan residues, another family of impurities the chromatography has to resolve away.
A real batch of IGF-1 DES proves itself: identity confirmed by mass spectrometry against its ~7,371.5 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of IGF-1 DES — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
DES(1-3)IGF-1 is a 67-residue analog of IGF-1 lacking the N-terminal Gly-Pro-Glu, produced recombinantly and folded to set IGF-1’s three disulfide bonds. As with IGF-1, correct disulfide pairing and refolding are the hard part, verified by peptide mapping and bioassay — biologic manufacturing, not solid-phase synthesis.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning IGF-1 DES, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
IGF-1 DES (DES(1-3)IGF-1) is a shortened form of IGF-1 missing its first three amino acids, which greatly reduces IGF-binding-protein binding and increases its local potency.
Both reduce IGFBP binding, but DES does it by truncation and is short-acting and locally potent, whereas LR3 adds modifications for long, systemic action.
The N-terminal tripeptide is part of what IGF-binding proteins grip; without it the peptide escapes sequestration and stays free and active.
No. It is a research compound (also common in cell culture), not FDA-approved, and prohibited in sport. This page is a research and educational reference.
Recombinant 191-amino-acid human growth hormone — a folded protein biologic identical in sequence to pituitary GH, not a synthetic research peptide.
ViewThe downstream effector of growth hormone — a 70-amino-acid recombinant protein, structurally a cousin of proinsulin, that carries out most of GH’s growth signal.
ViewA long-acting modified IGF-1 analog with reduced IGFBP binding and prolonged systemic activity.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.